Hangzhou Westan Pharmaceutical Technology

Hangzhou Westan Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages an advanced AI-driven drug discovery platform and computer-aided drug design (CADD) to target complex biological pathways in oncology and metabolic disorders. Westan's pipeline includes several proprietary programs, with its lead candidate, WST-01, a USP7 inhibitor, currently in Phase 1 clinical trials. By integrating structural biology with computational chemistry, the company aims to address unmet medical needs with high-precision medicines.